Should I buy or sell Treace Medical Concepts stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks .

What is Treace Medical Concepts' stock price target for 2024?

6 brokerages have issued 1 year price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they expect the company's share price to reach $19.58 in the next twelve months. This suggests a possible upside of 73.8% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts .

How have TMCI shares performed in 2024?

Treace Medical Concepts' stock was trading at $12.75 at the beginning of 2024. Since then, TMCI shares have decreased by 11.6% and is now trading at $11.27. View the best growth stocks for 2024 here .

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our TMCI earnings forecast .

How can I listen to Treace Medical Concepts' earnings call?

Treace Medical Concepts will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $62.20 million for the quarter, compared to analyst estimates of $60.56 million. Treace Medical Concepts had a negative net margin of 26.47% and a negative trailing twelve-month return on equity of 33.96%. The company's revenue for the quarter was up 24.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) EPS.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.0 million-$225.0 million, compared to the consensus revenue estimate of $223.2 million.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wealth Enhancement Advisory Services LLC (0.39%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace , John R Treace , John T Treace , Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan , Terry W Lubben and Thomas E Timbie . View institutional ownership trends .

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free TMCI Stock Alerts

$11.27

-0.13 (-1.14%)

(As of 04/18/2024 ET)

Compare

Today's Range: $11.03
▼
$11.42
50-Day Range: $11.27
▼
$15.86
52-Week Range: $5.27
▼
$27.70

Volume: 316,865 shs
Average Volume: 483,408 shs
Market Capitalization: $696.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.58

Get Treace Medical Concepts alerts:

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 73.8% Upside
$19.58 Price Target
Short Interest: Healthy
6.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.91) to ($0.79) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

441st out of 918 stocks

Surgical & Medical Instruments Industry

44th out of 91 stocks

3.4

Analyst's Opinion

Consensus Rating
Treace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Treace Medical Concepts has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.11% of the float of Treace Medical Concepts has been sold short.
Short Interest Ratio / Days to Cover
Treace Medical Concepts has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Treace Medical Concepts has recently decreased by 9.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Treace Medical Concepts does not currently pay a dividend.
Dividend Growth
Treace Medical Concepts does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TMCI.

2.0

News and Social Media Coverage

News Sentiment
Treace Medical Concepts has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for TMCI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.43% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.91) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Treace Medical Concepts is -13.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Treace Medical Concepts is -13.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Treace Medical Concepts has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TMCI Stock News Headlines

April 17, 2024 | finance.yahoo.com

Treace to Present at Bank of America Health Care Conference

April 16, 2024 | globenewswire.com

Treace Announces First Annual National Bunion Day

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 15, 2024 | investorplace.com

7 Stable Stocks for 50% Returns by Early 2025

April 14, 2024 | americanbankingnews.com

Treace Medical Concepts (NASDAQ:TMCI) Stock Price Down 5.2%

April 9, 2024 | globenewswire.com

Treace to Report First Quarter 2024 Financial Results

March 25, 2024 | globenewswire.com

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

March 1, 2024 | seekingalpha.com

Treace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcript

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 1, 2024 | finance.yahoo.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported And Analysts Have Been Lifting Their Price Targets

March 1, 2024 | morningstar.com

Treace Medical Concepts Inc

February 29, 2024 | finance.yahoo.com

Treace Medical Concepts Full Year 2023 Earnings: EPS Misses Expectations

February 29, 2024 | finance.yahoo.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Buy Rating on Treace Medical Concepts: Promising Financial Outlook and Strategic Product Innovation Drive Growth

February 27, 2024 | finance.yahoo.com

Treace Medical Concepts Inc (TMCI) Reports Robust Revenue Growth and Expands Surgeon Base in Q4 ...

February 27, 2024 | globenewswire.com

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance

February 20, 2024 | msn.com

Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates

February 20, 2024 | finance.yahoo.com

Earnings Preview: Treace Medical Concepts (TMCI) Q4 Earnings Expected to Decline

February 20, 2024 | finance.yahoo.com

TMCI Sep 2024 20.000 call

February 20, 2024 | finance.yahoo.com

TMCI Jun 2024 22.500 call

February 18, 2024 | finance.yahoo.com

TMCI Mar 2024 17.500 call

February 17, 2024 | finance.yahoo.com

TMCI Mar 2024 25.000 call

February 13, 2024 | uk.investing.com

Treace Medical Concepts Inc (TMCI)

February 7, 2024 | finance.yahoo.com

Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

February 2, 2024 | finance.yahoo.com

Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

February 1, 2024 | finance.yahoo.com

Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

January 31, 2024 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for Treace Medical Concepts (TMCI)

See More Headlines

Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:TMCI
CUSIP: N/A
CIK: 1630627
Web: www.treace.com
Phone: 904-373-5940
Fax: N/A
Employees: 516
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.58
High Stock Price Target: $27.50
Low Stock Price Target: $11.00
Potential Upside/Downside: +73.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,530,000.00
Net Margins: -26.47%
Pretax Margin: -26.47%
Return on Equity: -33.96%
Return on Assets: -19.99%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 4.40
Quick Ratio: 3.76

Sales & Book Value

Annual Sales: $187.12 million
Price / Sales: 3.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.24 per share
Price / Book: 5.03

Miscellaneous

Outstanding Shares: 61,760,000
Free Float: 46,668,000
Market Cap: $696.04 million
Optionable: Optionable
Beta: 0.27

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. John T. Treace (Age 52)
CEO, Founder & Director
Comp: $1.09M
Mr. Mark L. Hair CPA (Age 54)
Chief Financial Officer
Comp: $599.7k
Mr. Aaron J. Berutti (Age 45)
Senior Vice President of Sales
Comp: $484.22k
Mr. Terry W. Lubben (Age 59)
Senior Vice President of Operations
Ms. Julie D. Dewey (Age 63)
Chief Communications & Investor Relations Officer
Mr. Scot M. Elder J.D. (Age 49)
Chief Legal & Compliance Officer and Corporate Secretary
Mr. Nathan Minnich
Senior Vice President of Marketing
Mr. Daniel E. Owens (Age 52)
Chief Human Resources Officer
Dr. Sean F. Scanlan Ph.D. (Age 42)
Chief Innovation Officer
Ms. Shana Zink
Senior Vice President of Clinical Affairs, Medical Education & Reimbursement

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.
What is Treace Medical Concepts' stock price target for 2024?: 6 brokerages have issued 1 year price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they expect the company's share price to reach $19.58 in the next twelve months. This suggests a possible upside of 73.8% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.
How have TMCI shares performed in 2024?: Treace Medical Concepts' stock was trading at $12.75 at the beginning of 2024. Since then, TMCI shares have decreased by 11.6% and is now trading at $11.27.
View the best growth stocks for 2024 here.
When is Treace Medical Concepts' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our TMCI earnings forecast.
How can I listen to Treace Medical Concepts' earnings call?: Treace Medical Concepts will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Treace Medical Concepts' earnings last quarter?: Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $62.20 million for the quarter, compared to analyst estimates of $60.56 million. Treace Medical Concepts had a negative net margin of 26.47% and a negative trailing twelve-month return on equity of 33.96%. The company's revenue for the quarter was up 24.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) EPS.

What guidance has Treace Medical Concepts issued on next quarter's earnings?: Treace Medical Concepts issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.0 million-$225.0 million, compared to the consensus revenue estimate of $223.2 million.
When did Treace Medical Concepts IPO?: Treace Medical Concepts (TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.
Who are Treace Medical Concepts' major shareholders?: Treace Medical Concepts' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wealth Enhancement Advisory Services LLC (0.39%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends.
How do I buy shares of Treace Medical Concepts?: Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

Treace Medical Concepts MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Treace Medical Concepts Stock (NASDAQ:TMCI)

TMCI Stock Price History

TMCI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TMCI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™